Current progress in clinical, molecular, and genetic aspects of adult fibromuscular dysplasia

Archive ouverte

Persu, Alexandre | Dobrowolski, Piotr | Gornik, Heather, L | Olin, Jeffrey, W | Adlam, David | Azizi, Michel | Boutouyrie, Pierre | Bruno, Rosa Maria | Boulanger, Marion | Demoulin, Jean-Baptiste | Ganesh, Santhi, K | J. Guzik, Tomasz | Januszewicz, Magdalena | Kovacic, Jason, C | Kruk, Mariusz | de Leeuw, Peter | Loeys, Bart, L | Pappaccogli, Marco | Perik, Melanie, H a M | Touzé, Emmanuel | van der Niepen, Patricia | van Twist, Daan, J L | Warchoł-Celińska, Ewa | Prejbisz, Aleksander | Januszewicz, Andrzej

Edité par CCSD ; Oxford University Press (OUP) -

International audience. Abstract Fibromuscular dysplasia (FMD) is a non-atherosclerotic vascular disease that may involve medium-sized muscular arteries throughout the body. The majority of FMD patients are women. Although a variety of genetic, mechanical, and hormonal factors play a role in the pathogenesis of FMD, overall, its cause remains poorly understood. It is probable that the pathogenesis of FMD is linked to a combination of genetic and environmental factors. Extensive studies have correlated the arterial lesions of FMD to histopathological findings of arterial fibrosis, cellular hyperplasia, and distortion of the abnormal architecture of the arterial wall. More recently, the vascular phenotype of lesions associated with FMD has been expanded to include arterial aneurysms, dissections, and tortuosity. However, in the absence of a string-of-beads or focal stenosis, these lesions do not suffice to establish the diagnosis. While FMD most commonly involves renal and cerebrovascular arteries, involvement of most arteries throughout the body has been reported. Increasing evidence highlights that FMD is a systemic arterial disease and that subclinical alterations can be found in non-affected arterial segments. Recent significant progress in FMD-related research has led to improve our understanding of the disease’s clinical manifestations, natural history, epidemiology, and genetics. Ongoing work continues to focus on FMD genetics and proteomics, physiological effects of FMD on cardiovascular structure and function, and novel imaging modalities and blood-based biomarkers that can be used to identify subclinical FMD. It is also hoped that the next decade will bring the development of multi-centred and potentially international clinical trials to provide comparative effectiveness data to inform the optimal management of patients with FMD.

Suggestions

Du même auteur

The European/International Fibromuscular Dysplasia Registry and Initiative (FEIRI)—clinical phenotypes and their predictors based on a cohort of 1000 patients

Archive ouverte | Pappaccogli, Marco | CCSD

International audience. Abstract Aims Since December 2015, the European/International Fibromuscular Dysplasia (FMD) Registry enrolled 1022 patients from 22 countries. We present their characteristics according to di...

First international consensus on the diagnosis and management of fibromuscular dysplasia

Archive ouverte | Gornik, Heather | CCSD

International audience

Genetic Study of PHACTR1 and Fibromuscular Dysplasia, Meta-Analysis and Effects on Clinical Features of Patients

Archive ouverte | Bouatia-Naji, Nabila | CCSD

International audience

Chargement des enrichissements...